Teladoc Health Inc (NYSE:TDOC) COO David William Sides Sells 3,117 Shares
Teladoc Health Inc (NYSE:TDOC) COO David William Sides sold 3,117 shares of the firm’s stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $216.67, for a total transaction of $675,360.39. Following the transaction, the chief operating officer now directly owns 7,299 shares in the company, valued at $1,581,474.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Shares of NYSE:TDOC opened at $237.63 on Friday. The firm has a market cap of $17.69 billion, a PE ratio of -185.65 and a beta of 0.44. The firm’s fifty day moving average is $207.13 and its 200-day moving average is $158.76. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.14 and a current ratio of 6.14. Teladoc Health Inc has a 52 week low of $54.58 and a 52 week high of $240.00.
Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, July 29th. The health services provider reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.11). The business had revenue of $241.03 million for the quarter, compared to analyst estimates of $220.49 million. Teladoc Health had a negative return on equity of 10.23% and a negative net margin of 13.22%. Teladoc Health’s revenue for the quarter was up 85.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.41) EPS. Sell-side analysts forecast that Teladoc Health Inc will post -1.15 EPS for the current year.
Several research analysts have recently commented on the stock. Credit Suisse Group raised their target price on shares of Teladoc Health from $165.00 to $225.00 and gave the stock a “neutral” rating in a report on Thursday. Stifel Nicolaus increased their price target on shares of Teladoc Health from $144.00 to $205.00 and gave the stock a “hold” rating in a research report on Thursday. KeyCorp increased their price target on shares of Teladoc Health from $195.00 to $240.00 and gave the stock an “overweight” rating in a research report on Thursday. Royal Bank of Canada increased their price target on shares of Teladoc Health from $200.00 to $235.00 and gave the stock an “outperform” rating in a research report on Thursday. Finally, Argus began coverage on shares of Teladoc Health in a research report on Monday, July 13th. They set a “buy” rating and a $280.00 price target on the stock. Fifteen equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Teladoc Health currently has an average rating of “Hold” and a consensus price target of $195.04.
Teladoc Health Company Profile
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Recommended Story: Why Invest in High-Yield Dividend Stocks?
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.